ARTICLE | Preclinical News
Aminex shows MYCN is a regulator of the polyamine pathway
February 1, 2019 8:31 PM UTC
Researchers from Aminex Therapeutics Inc. (Seattle, Wash.) and University of New South Wales showed that the MYCN oncogene is a direct regulator of the polyamine pathway, suggesting a new approach to hitting the otherwise undrugggable MYCN target.
Increased levels of MYCN (v-myc myelocytomatosis viral related oncogene neuroblastoma derived; NMYC) occur in 40-50% of high-risk neuroblastomas. According to Aminex, no compounds have been able to directly target MYCN...